



|   |                 |  |         |                 |          |                            |    |
|---|-----------------|--|---------|-----------------|----------|----------------------------|----|
| U.S. Department of Commerce, Patent and Trademark Office  |                 |  |         | Atty Docket No. |          | Serial No.                 |    |
| PB-0016 US  |                 |  |         | PB-0016 US      |          | 09/05,952                  |    |
| LIST OF REFERENCES CITED BY APPLICANTS  |                 |  |         | Applicant(s)    |          |                            |    |
| (Use several sheets if necessary)   |                 |  |         | Walker et al.   |          |                            |    |
| Filing Date   |                 |  |         | Group           |          |                            |    |
| November 27, 2001   |                 |  |         | 164             |          |                            |    |
| U.S. Patent Documents   |                 |  |         |                 |          |                            |    |
| *Examiner Initial   | Document Number | Date   | Name    | Class           | Subclass | Filing Date If Appropriate |    |
|   |                 |  |         |                 |          |                            |    |
| Foreign Patent Documents  |                 |  |         |                 |          |                            |    |
|   |                 |  |         |                 |          | Translation                |    |
|   | Document        | Date   | Country | Class           | Subclass | Yes                        | No |
|   |                 |  |         |                 |          |                            |    |
| OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)  |                 |  |         |                 |          |                            |    |
| RH  | 1               | Nestler, J.E., "Insulin-like growth factor H is a potent inhibitor of the aromatase activity of human placental cytotrophoblasts", <u>Endocrinology</u> , 127:2064-2070 (1990)--abstract only.   |         |                 |          |                            |    |
|   | 2               | Jain, L., "Effect of pregnancy-induced and chronic hypertension on pregnancy outcome", <u>J. Perinatol.</u> , 17:425-427 (1997)--abstract only.  |         |                 |          |                            |    |
|   | 3               | Innes, K.E. and J.H. Wimsatt, "Pregnancy-induced hypertension and insulin resistance: evidence for a connection", <u>Acta Obstet. Gynecol. Scand.</u> , 78:263-284 (1999)--abstract only.  |         |                 |          |                            |    |
|   | 4               | Visser, W. and H.C. Wallenburg, "Prediction and prevention of pregnancy-induced hypertensive disorders", <u>Baillieres Best Pract. Res. Clin. Obstet. Gynaecol.</u> , 13:131-156 (1999)--abstract only.  |         |                 |          |                            |    |
|   | 5               | Geller, D.S. et al., "Activating Mineralocorticoid Receptor of Mutation in Hypertension Exacerbated by Pregnancy", <u>Science</u> , 289:119-123 (2000).  |         |                 |          |                            |    |
|   | 6               | Okubo, K. et al., "Aromatase and estrogen 2-hydroxylase activities of human placental microsomes in pregnancy-induced hypertension", <u>Endocr. J.</u> , 43:363-368 (1996)--abstract only.   |         |                 |          |                            |    |
|   | 7               | Valensise, H. et al., "Increased expression of low-affinity insulin receptor isoform and insulin/insulin-like growth factor-I hybrid receptors in term placenta from insulin-resistant women with gestational hypertension", <u>Diabetologia</u> , 39:952-960 (1996)--abstract only. |         |                 |          |                            |    |
| RH  | 8               | Hadden, D.R., "How to improve prognosis in type 1 diabetic pregnancy. Old problems, new concepts", <u>Diabetes Care</u> , 22 Suppl. 2:B104-B108 (1999)--abstract only.   |         |                 |          |                            |    |
| Examiner  |                 | Date Considered  |         |                 |          |                            |    |
| [Signature]   |                 | 7/8/03   |         |                 |          |                            |    |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant. |                 |  |         |                 |          |                            |    |

RECEIVED

MAR 12 2002

RECEIVED

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

|  |                 |  |
|--|-----------------|--|
|              | 9               | Nestler, J.E., "Modulation of aromatase and P450 cholesterol side-chain cleavage enzyme activities of human placental cytotrophoblasts by insulin and insulin-like growth factor I", <u>Endocrinology</u> , 121:1845-1852 (1987)--abstract only.   |
|  | 10              | Nestler, J.E., "Insulin and insulin-like growth factor-I stimulate the 3 beta-hydroxysteroid dehydrogenase activity of human placental cytotrophoblasts", <u>Endocrinology</u> , 125:2127-2133 (1989)--abstract only.  |
|  | 11              | Nestler, J.E., "Regulation of the aromatase activity of human placental cytotrophoblasts by insulin, insulin-like growth factor-I, and -II", <u>J. Steroid Biochem. Mol. Biol.</u> , 44:449-457 (1993)--abstract only.   |
|  | 12              | Diamant, Y.Z., "The human placenta in diabetes mellitus", <u>Isr. J. Med. Sci.</u> , 27:493-497 (1991)--abstract only.   |
|  | 13              | Olszewski, J. et al., "Changes in levels of human placenta lactogen (hPL), a progesterone, and estriol, in blood serum and estrogens in urine during gestational diabetes mellitus", <u>Ginekol. Pol.</u> , 66:145-150 (1995)--abstract only.  |
|  | 14              | Gardner, M.O. et al., "Meternal serum concentrations of humans placental lactogen, estradiol and pregnancy specific beta 1-glycoprotein and fetal growth retardation", <u>Acta Obstet. Gynecol. Scand. Suppl.</u> , 165:56-58 (1997)--abstract only.   |
|  | 15              | Juriscicova, A. et al., "Variability in the expression of trophoctodermal markers beta-human chorionic gonadotrophin, human leukocyte antigen-G and pregnancy specific beta-1 glycoprotein by the human blastocyst", <u>Hum. Reprod.</u> , <u>Hum. Reprod.</u> , 14:1852-1858 (1999)--abstract only. |
|  | 16              | Qin, Q.P. et al., "Double-monoclonal immunofluorometric assays for pregnancy-associated plasma protein A/proeosinophil major basic protein (PAPP-A/promBP) complex in first-trimester maternal serum screening for Down syndrome", <u>Clin. Chem.</u> , 43:2323-2332 (1997)--abstract only.          |
|  | 17              | De Biaso, P. et al., "First-trimester screening for Down syndrome using nuchal translucency measurement with free beta-hCG and PAPP-A between 10 and 13 weeks of pregnancy--the combined test", <u>Prenat. Diagn.</u> , 19:360-363 (1999)--abstract only.  |
| R+   | 18              | Spencer, K., "The influence of smoking on maternal serum PAPP-A and free beta hCG levels in the first trimester of pregnancy", <u>Prenat. Diagn.</u> , 19:1065-1066 (1999)--abstract only.   |
|  |                 |  |
|  |                 |  |
|  |                 |  |
|  |                 |  |
|  |                 |  |
| Examiner  | Date Considered | 9/9/03   |

RECEIVED  
MAR 12 2002  
TECH CENTER 1600/2800

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.